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Abstract: Idiopathic nephrotic syndrome (INS) in children is most commonly caused by primary glomerulopa-
thies. Morphological lesions observed in INS might be secondary to inflammatory factors of mainly extra-renal
origin. The vascular endothelial growth factor (VEGF) family is regarded as playing a crucial role in this path-
omechanism. The aim of the present work was to analyze the possible relation between VEGF-C and VEGF
receptor (VEGFR)-2 expressions at electron microscopy level in different INS cases. The study group com-
prised 18 children with minimal change disease (MCD), 30 patients diagnosed with diffuse mesangial prolifera-
tion (DMP) and 11 subjects with focal segmental glomerulosclerosis (FSGS). An indirect immunohistochemical
assay employing monoclonal anti-VEGF-C and anti-VEGFR-2 antibodies was applied in the study. The immuno-
histochemical expression of VEGF-C within podocyte cytoplasm was significantly increased in DMP subjects
who were resistant to steroids and in all FSGS patients compared to MCD children and controls (p < 0.05).
VEGF-C over-expression in these cases was followed by downregulation of VEGFR-2. Nephrotic syndrome pro-
gression correlates with the downregulation of podocyte VEGFR-2. For this reason, decreased VEGFR-2 expres-
sion in the podocyte processes of children with idiopathic nephrotic syndrome might be regarded as a potent
factor of unfavorable prognosis. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 472–478)
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Introduction
The vascular endothelial growth factor (VEGF) fam-
ily is composed of five members: VEGF (sometimes
called VEGF-A), placenta growth factor (PlGF),
VEGF-B, VEGF-C and VEGF-D [1]. VEGFs belong
to the platelet-derived growth factor (PDGF)/VEGF
superfamily of secreted dimeric glycoprotein growth
factors that contain a cysteine knot motif [1]. The
VEGF ligands bind with differing specificities to three
mostly endothelial transmembrane tyrosine kinase
receptors including: VEGFR-1/fms-like tyrosine ki-
nase 1 (Flt1), VEGFR-2/human kinase insert domain
receptor (KDR)/mouse fetal liver kinase 1 (Flk1) and
VEGFR-3/fms-like tyrosine kinase 4 (Flt4) [1].
VEGFR-2 manifests the widest spectrum of bind-
ing ligands. It might process with all the VEGF fam-
ily members except PlGF and VEGF-B [2]. Interest-
ingly, VEGF signaling through VEGFR-2 is consid-
ered as a major angiogenic pathway [1]. VEGFR-1
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seems to act as a negative regulator of VEGF-medi-
ated angiogenesis during development, and as a stim-
ulator of pathological angiogenesis when activated by
its specific ligands: PlGF and VEGF-B [1, 2]. For
VEGF-B, with very limited angiogenic potential,
a new role has been identified in the regulation of lipid
metabolism in the cardiac muscle [2]. VEGF-C and
VEGF-D are believed to induce lymphangiogenesis
via VEGFR-3. They have been proven to activate the
development of lymphatic vessels in different tumors
and, consequently, stimulate metastases [3]. VEGF-C
seems to be a much more pleiotropic molecule than
VEGF-D. It is expressed in bone marrow hemato-
poietic cells [4, 5], developing nerve fibers [6] and the
kidneys [7].
The most frequent reason for primary glomerulo-
pathies in children is idiopathic nephrotic syndrome
(INS), reflecting impaired glomerular permeability
[8]. Morphological lesions observed in INS might be
secondary to inflammatory factors of mainly extra-
-renal origin.
Some (e.g. interleukins and VEGF-C) are regard-
ed as playing a fundamental role in this pathomecha-
nism [7, 9, 10]. Interestingly, VEGF-C could be ex-
pressed both in cultured and tissue podocytes. In cul-
tured podocytes, VEGF-C acts in an autocrine man-
ner to promote their survival [10]. In other studies,
VEGF-C has been found to increase filtration barri-
er permeability and has been regarded as a factor of
unfavorable prognosis in nephrotic syndrome chil-
dren [7]. This apparent discrepancy may be explained
by detailed, molecular studies of VEGF-C receptors
expressions in filtration barrier elements (podocytes,
basement membrane and endothelial cells). Studies
performed by Foster et al. revealed VEGF-C does
not act in cultured podocytes via VEGFR-3 [10].
They concluded that the receptor or receptor com-
plex activated has yet to be elucidated. Because
VEGF-C is able to induce its biological effects via
VEGFR-2 or VEGFR-3, the aim of the present study
was to evaluate both VEGFR-2 and VEGFR-3 ex-
pressions in filtration barrier elements at electron
microscopy (EM) level using the immuno-gold tech-
nique for the detection of antigen-antibody complex-
es in biopsy material.
Material and methods
Patients. The study group was composed of children diag-
nosed with INS, hospitalized between 2003 and 2006 in the
Department of Pediatric Cardiology and Nephrology,
Poznan University of Medical Sciences. Two hundred and
eighty-six children were referred to our clinic, and evidence
of proteinuria was found in 146 of them. Eighty-four pa-
tients (44 boys and 40 girls), following International Study
for Kidney Diseases in Children recommendations, under-
went a biopsy [11]. The indications included primary idio-
pathic glomerulonephritis (n = 36), steroid-resistant
nephrotic syndrome (SRNS) (n = 23) and secondary glomer-
ulonephritis (n = 25, who were excluded from further analy-
sis). Kidney biopsy was performed after eight weeks of high
dose steroid treatment in SRNS children and in all the chil-
dren recognized with primary idiopathic glomerulonephritis
before commencement of the treatment. No study participants
were administered at the time of kidney biopsy any  anti-hy-
pertensive drugs or immunosuppressants, apart from steroids.
Diagnoses of minimal change disease (MCD), diffuse
mesangial proliferation (DMP) and focal segmental glom-
erulosclerosis (FSGS) were established according to WHO
criteria and were based on the number of cells per mesan-
gial area (four or more cells for DMP, n = 30 patients) or
the presence of at least one sclerotic focus in kidney biopsy
material for FSGS (n = 11 subjects) [12]. Eighteen chil-
dren were diagnosed with MCD. In all, the study group was
composed of 59 participants.
INS has been classically characterized by the absence of
significant deposits in immunofluorescence microscopy (IF),
except for FSGS and/or hyalinosis in FSGS, which bind IgM
and C3 antiserum [13]. There were no significant differenc-
es between the various categories defined by IF [14]. In 25
patients with DMP, the presence of IgM and/or IgG within
the mesangial area was observed without electron-dense
deposits. No IgA nephropathy was diagnosed in the sub-
jects. The relevant data is presented in Table 1.
The Ethics Committee of Poznan University of Medical
Sciences approved the research protocol and the parents of all
study participants gave informed consent for the investigation.
Controls. Ten age- and sex-matched children in whom to-
tal nephrectomy due to the presence of Wilms tumor had
been performed served as a control group. All of these sub-
jects had a normal renal function. Macroscopically normal-
appearing kidney tissue was rinsed with PBS, fixed in PBS-
-buffered 4% paraformaldehyde with 0.05% glutaraldehyde
for 1 h on ice, and subsequently fixed in 1% glutaraldehyde
for 0.5 h at room temperature. The material was then saved
for the subsequent procedure.
Immunoelectron microscopy (post-embedding tech-
nique). Similarly to control tissue, kidney biopsy specimens
were fixed in PBS-buffered 4% paraformaldehyde with
0.05% glutaraldehyde and subsequently in 1% glutaralde-
hyde. The material was then incubated in the same buffer
containing 2.3 M sucrose overnight, and subsequently em-
bedded in Lowicryl HM 20 (Polysciences Europe, Eppel-
heim, Germany).
For immuno-gold labeling of VEGF-C, VEGFR-2 and
VEGFR-3, ultrathin sections were transferred to 200-mesh
nickel grids coated with 3% collodion. After blocking of
nonspecific labeling with 50 mM glycine and 2% gelatin,
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0.5% acetylated BSA ultrathin sections were incubated over-
night at 8°C with anti-VEGF-C antibody (NB110-61022,
Novus Biological, Cambridge, UK; diluted 1:20), with anti-
-VEGFR-2 antibody (NB100-686, Novus Biological; diluted
1:50) or with anti-VEGFR-3 antibody (NBP1-03254, Novus
Biological; diluted 1:20). All of them were subsequently
detected with goat anti-rabbit IgG (NB100-2332, Novus
Biological; diluted 1:50) and coupled to 20-nm gold parti-
cles (Dianova, Hamburg, Germany). Sections were coun-
terstained with 2% uranyl acetate and Reynold’s lead cit-
rate, and examined with a Zeiss EM 900.
Specificity controls were performed by omission of the pri-
mary antibody using in place of normal goat IgG serum
(sc-3887, Santa Cruz Biotechnology, Santa Cruz, CA, USA;
diluted 1:50) or PBS. Positive immuno-labeling was performed
using VEGF-C, VEGFR-2 and VEGFR-3 antibodies incubat-
ed in appropriate positive tissues (neuroblastoma cancer cells,
blood vessel endothelial cells and lymphatic endothelial cells
respectively) as well as with anti-podocalyxin primary antibod-
ies (sc-33138, Santa Cruz Biotechnology; diluted 1:50) [15].
Finally, 5–6 EM images demonstrating individual im-
muno-gold incubations were analyzed for each study par-
ticipant (patient or control).
Quantitative and statistical analysis. The analysis was
performed blind on coded samples. Continuous or inter-
val-related variables were expressed as mean ± SD. Data
was compared using Student’s t-test, or one-way analysis
of variance test (ANOVA) where appropriate. Variations
in antigen distribution within renal glomeruli were evalu-
ated using MicroImage v. 4.0 morphometric software
(Olympus, MS Windows XP). An average density of mark-
er expression on selected area (number of gold particles
per 1 μm2 using MicroImage v. 4.0) was measured and com-
pared to results obtained in the control group as well as
among MCD, DMP and FSGS patients. Immuno-gold
stained slides were examined field per field by two experi-
enced investigators to identify the area showing the most
intense concentration of gold particles (‘hot spot’). The
selection of hot spots was based on observing restricted
areas with an impression of a higher density of gold parti-
cles. Three hot spots from each image were then photo-
graphed, and an average of gold particles per 1 μm2 was
counted for consequent statistical analysis. Any black dot
that was clearly separated from adjacent tissues was con-
sidered as a single, countable gold particle. Differences
between groups were then evaluated by ANOVA test. To
determine the significance between group means in the
analysis of variance, the nearest significant difference test
(Tukey test) was used as the multiple comparison analysis.
Significance was set at p < 0.05.
Results
Clinical course
According to the histological evaluation of the kid-
ney biopsy, the patients comprising the study group
were divided into MCD, DMP and FSGS subjects.
All MCD children manifested steroid sensitive course
of nephrotic syndrome (SSNS), while all FSGS sub-
jects revealed steroid resistant nephrotic syndrome
(SRNS). Eighteen children diagnosed with DMP de-
veloped SSNS (DMP-s subgroup) and 12 patients
demonstrated SRNS course (DMP-r subgroup). All
the study participants observed with SRNS had a sig-
nificantly higher proteinuria and significantly lower
concentration of serum albumin. Moreover, there was
a significantly higher percentage of patients with eval-
uated erythrocyturia in DMP-s and FSGS patients
compared to MCD and DMP-r children. Finally,
FSGS children had a significantly lower glomerular
filtration rate (GFR). Detailed information is present-
ed in Table 1.
Table 1. Clinical and biochemical characteristics of the study population at the time of kidney biopsy (after eight-week
steroid treatment)
Characteristics Study group
MCD DMP-s DMP-r FSGS
Number of patients 18 18 12 11
Age (years) 10.7 (6–18) 10 (5–16) 10 (5–14) 11.5 (6–16)
Sex (M/F) 10/8 8/10 8/4 6/5
Proteinuria [mg/kg/24 h] 41 ± 8 30 ± 10 90 ± 23** 56 ± 11*
Erythrocyturia (% of patients) 22.2 50.0* 33.4 72.7**
GFR [ml/min/1,73 m2] 98 ± 8 105 ± 11 108 ± 15 85 ± 12*
Serum albumin [g/dl] 2.9 ± 0.8 3.1 ± 0.8 2.5 ± 0.3 2.2 ± 0.5
MCD — minimal change disease; DMP-s — diffuse mesangial proliferation (sensitive to steroids); DMP-r — diffuse mesangial proliferation
(resistant to steroids); FSGS — focal segmental glomerulosclerosis; erythrocyturia — number of red blood cells in urine > 2 cell per high power
field; GFR — glomerular filtration rate; *p < 0.05; **p < 0.0001
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Expressions of both VEGFR-2 and podocalyxin were
demonstrated in all the children comprising the con-
trol group. VEGFR-2 was present within endothelial
cells (ECs) of filtration barrier while podocalyxin was
expressed both in ECs and podocyte processes (Fig-
ure 1). These subjects presented also  single gold par-
ticles demonstrating VEGF-C and VEGFR-3 expres-
sions within glomerular ECs (data not shown). A sim-
ilar expression of VEGFR-2 within ECs, as well as
podocalyxin in ECs and podocytes were revealed in
all the patients comprising the study group. None of
the studied children, however, demonstrated the im-
munohistochemical expression of VEGFR-3 within
filtration barrier elements (Table 2).
Interestingly, all the patients comprising the study
group expressed VEGF-C in podocyte processes while
VEGFR-2, except for ECs, was also present within vis-
ceral cells of Bowman capsule. The density of gold par-
ticles differed, however, between subsequent sub-groups.
SSNS children (MCD + DMP-s) were evaluated
with a relatively high expression of VEGFR-2 in
podocytes (Figure 2) followed by a significantly low-
er expression of VEGF-C (Figure 3).
In SRNS patients (DMP-r + FSGS), the situation
was exactly the opposite: a relatively low expression
of VEGFR-2 in visceral cells of Bowman capsule (Fig-
ure 4) was followed by a definitely higher expression
of VEGF-C within podocytes (Figure 5). VEGF-C,
as presented in Figure 4, was also expressed within
glomerular ECs. Relevant data and statistical analy-
sis are summarized in Table 2.
In addition, Figure 2 demonstrates the presence
of VEGFR-2 related gold particles not only within
podocyte foot processes and glomerular ECs, but also
in glomerular basement membrane (GBM). More-
over, the concentration of gold particles within GBM
was equal to the area concentration of VEGFR-2 re-
lated gold particles in glomerular ECs.
Taken together, an unfavorable course of INS (de-
fined by resistance to steroids) correlated to an in-
creased expression of VEGF-C within podocytes and
decreased (as compared to SSNS patients) expression
of VEGFR-2 within visceral cells of Bowman capsule.
Discussion
Our study has demonstrated — for the first time —
expression of VEGF-C at electron microscopy level
within tissue podocytes of children diagnosed with
INS. Although VEGF-C presence was also detect-
Figure 1. Podocalyxin immuno-gold labeling in the control
kidney specimen. The presence of gold particles is visible
within glomerular endothelial cells (ECs) and podocytes
(asterisks). Basement membrane (BM) is immuno-negative;
Er — erythrocyte; original magnification × 21,560
Table 2. Immunohistochemical expression of studied antigens within filtration barrier elements at the electron microsco-
py level
Antigen Localization Density of marker expression Controls
MCD DMP-s DMP-r FSGS
VEGF-C Podocyte 0.7 ± 0.2 0.9 ± 0.2 1,8 ± 0,6* 1,9 ± 0,7* 0,0
Endothelial cells 0.0 0.0 0.9 ± 0,4** 0,8 ± 0,3** 0,3 ± 0,1
VEGFR-2 Podocyte 1.1 ± 0.4 1.3 ± 0.4 0,5 ± 0,1* 0,4 ± 0,1* 0,0
Endothelial cells 0.6 ± 0.2 0.6 ± 0.2 0,7 ± 0,2 0,5 ± 0,1 0,5 ± 0,1
Podocalyxin Podocyte 3.1 ± 0.9 3.4 ± 0.8 2,9 ± 1.0 3,2 ± 0,9 2,8 ± 0,7
Endothelial cells 2.8 ± 0.6 2.9 ± 0.4 2,7 ± 0,5 2,8 ± 0,5 2,6 ± 0,7
VEGFR-3 Endothelial cells No expression 0.4 ± 0.1
Density of marker expression — number of gold particles per 1 μm2: MCD — minimal change disease; DMP-s — diffuse mesangial proliferation
(sensitive to steroids); DMP-r — diffuse mesangial proliferation (resistant to steroids); FSGS — focal segmental glomerulosclerosis;
VEGF — vascular endothelial growth factor; VEGFR — vascular endothelial growth factor receptor; *p < 0.05; **p < 0.0001
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Figure 2. VEGFR-2 expression within filtration barrier
elements in a six year-old child diagnosed with minimal
change disease. The presence of gold particles is clearly
visible within glomerular endothelial cells (ECs) as well as
within podocytes (asterisks). Few dots visible within
basement membrane might refer to unspecific staining;
original magnification × 35,970
Figure 3. Electron microscope immuno-gold labeling
of VEGF-C in a six year-old child diagnosed with
minimal change disease. The marker is exclusively
present within podocytes (asterisks). Basement mem-
brane (BM) as well as glomerular endothelial cells
(ECs) are immuno-negative. Er — erythrocyte;
original magnification × 27,800
Figure 4. A nine year-old child with a diagnosis of resistant
to steroids diffuse mesangial proliferation. Similarly to Figure
2, VEGFR-2 expression is present within glomerular endo-
thelial cells (ECs). Immunoelectron microscopy (post-embed-
ding technique); original magnification × 27,800
Figure 5. Immunocytochemical expression of VEGF-C at
electron microscopy level in kidney biopsy of a nine year-
old child recognized with resistant to steroids diffuse
mesangial proliferation. Numerous VEGF-C related gold
particles visible within podocytes (asterisks) and glomeru-
lar endothelial cells (ECs). Basement membrane (BM) is
free of VEGF-C expression; original magnification × 46,460
ed in control tissue, its expression was significantly
higher in all the patients who developed resistance
to steroids. This observation corresponds with  pre-
vious reports by Foster et al. who proved expression
of VEGF-C and VEGFR-3 under normal conditions
in the human kidney by immunohistochemistry and
the immuno-gold technique [9, 10]. Our previous
studies, based on classical bright field microscopy,
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have revealed VEGF-C might be regarded as a fac-
tor of unfavorable prognosis in patients diagnosed
with INS [7].
On the other hand, increased VEGF-C expression
in SRNS children has, most probably, no nephro-pro-
tective effect that could be expected analyzing its bi-
ological meaning in cultured podocytes [10]. The stud-
ies performed by Foster et al. reported that VEGF-C
is a factor promoting cultured podocyte survival but
not acting via VEGFR-3 [10]. The authors suggested
there was another receptor binding VEGF-C in
podocytes. The same scientific team, but in a differ-
ent publication, proved VEGF-C to increase glomer-
ular cell monolayer integrity via VEGFR-2, and ob-
served glomerular ECs to express VEGFR-3 in tis-
sue sections and culture [16].
These results, in part, supplement our observa-
tions. The limit of all immunocytochemical tech-
niques, including the immuno-gold procedure, is the
impossibility of differentiating whether VEGF-C is
expressed in tissue per se or if it is bound to one of its
receptors. For this reason, a much more credible fac-
tor demonstrating a tissue status of VEGF-C/VEG-
FR-2 interaction is VEGFR-2. We suggest that VEG-
FR-2 is an essential receptor for VEGF-C, acting both
in podocytes as well as in glomerular ECs. That hy-
pothesis is most of all based on our remark indicating
podocyte VEGFR-2 expression is downregulated when
VEGF-C becomes more strongly expressed. Interest-
ingly, VEGFR-2 expression in glomerular ECs is con-
stant (no significant differences between the control
and the study group, as well as among subsequent stud-
ied sub-groups). Only podocyte VEGFR-2 expression
varied between SSNS and SRNS patients. The exact
mechanism of this process is yet to be investigated.
It must be emphasized that VEGFR-2 might be
downregulated by immunosuppressive drugs, includ-
ing steroids [17]. Several reports have described the
VEGFR-2 downregulation process during neuroblas-
toma progression [18], in pancreatic-islet tumor [19]
as well as in different non-cancerous models of an-
giogenesis [20]. Interestingly, SRNS patients ex-
pressed VEGF-C not only within podocytes but also
in glomerular ECs (VEGF-C was not expressed in
glomerular ECs in SSNS subjects nor in controls).
This might suggest an autocrine VEGF-C alternat-
ing activity of glomerular ECs.
The question, however, as to whether VEGF-C
improves ECs monolayer or increases vascular per-
meability, remains open. Similarly, a potent VEGF-
C/VEGFR-2 interaction in regulating podocyte func-
tion and glomerular filtration barrier integrity in SSNS
and SRNS is not yet clear and cannot be explained by
the present report.
VEGF-C expression during embryonic develop-
ment is observed both in places where the first lymph
sacs develop and in regions of lymph vessel sprouting
[21, 22]. The binding affinity of VEGF-C for its re-
ceptors is regulated by proteolytic processing of the
pro-peptides. Its affinity for VEGFR-3 increases with
processing, while only the mature forms of VEGF-C
bind VEGFR-2 [23, 24]. It seems to be also possible
that the mature form of VEGF-C has a much more
expanded tissue activity, not only restricted to devel-
oping lymph vessels. This significant pleiotropy is,
however, dependent on the type of receptor present
in a tissue [2]. For this reason, VEGF-C/VEGFR-2
[25, 26] and VEGF-C/VEGFR-3 signaling pathway
dualism [26, 27] might explain a binary identity of
VEGF-C manifestation.
Our observation might also be interesting from an-
other point of view. Some of the anti-angiogenic drugs
are directed on blocking their specific receptors
[28, 29]. If our elaboration could be expanded in the
future to VEGF-C/VEGFR-2 activity in neoplasms,
it might significantly influence the future anti-angio-
genic therapy and explain some of the observed med-
ication discrepancy in these patients.
In conclusion, nephrotic syndrome progression
correlates with the downregulation of podocyte VEG-
FR-2 expression. For this reason, VEGFR-2 de-
creased expression in the podocyte processes of chil-
dren with idiopathic nephrotic syndrome might be
regarded as a potent factor of unfavorable prognosis.
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